Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL. Harrison: Medicina Interna. 18 ed. Porto Alegre:AMGH, 2013.

Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, et al. Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections. Am J Gastroenterol 2013; 108:478-498; doi: 10.1038/ajg.2013.4; published online 26 February 2013.

Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31(5):431-455.

McFarlane M, Hajkowicz K. Controlling Clostridium difficile. Aust Prescr 2013; 36: 121-4.

Bouza E, Burillo A, Muñoz P. Antimicrobial Therapy of Clostridium difficile-Associated Diarrhea. Med Clin N Am 90 (2006); 1141-63. doi:10.1016/j.mcna.2006.07.011.

Drekonja DM, Butler M, MacDonald R, Bliss D, Filice GA, Rector TS, et al. Comparative Effectiveness of Clostridium difficile Treatments: A Systematic Review. Ann Intern Med. 2011; 155(12): 839-47.

Crook DW, Walker AS, Kean Y, Weiss K, Cornely OA, Miller MA, et al. Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials. Clinical Infectious Diseases 2012; 55(S2): S93-103. DOI: 10.1093/cid/cis499.

Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, et al. Fidaxomicin versus Vancomycin for Clostridium difficile Infection. N Engl J Med 2011; 364(5): 422-31.

Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. The Lancet 2012; 12:281-9.

Iarikov DE, Alexander J, Nambiar S. Hypersensitivity Reactions Associated With Fidaxomicin Use. Clinical lnfectious Diseases 2014;58 (4):537-9